...
首页> 外文期刊>Cellular Physiology and Biochemistry >Extracellular Vesicles Secreted by Human Urine-Derived Stem Cells Promote Ischemia Repair in a Mouse Model of Hind-Limb Ischemia
【24h】

Extracellular Vesicles Secreted by Human Urine-Derived Stem Cells Promote Ischemia Repair in a Mouse Model of Hind-Limb Ischemia

机译:人尿衍生干细胞分泌的细胞外囊泡在后肢缺血小鼠模型中促进缺血修复。

获取原文
           

摘要

Background/Aims Our previous studies have shown that human urine-derived stem cells (USCs) have great potential as a cell source for cytotherapy and tissue engineering and that extracellular vesicles (EVs) secreted by USCs (USCs-EVs) can prevent diabetes-induced kidney injury in an animal model. The present study was designed to evaluate the effects of USCs-EVs on ischemia repair. Methods USCs-EVs were isolated and purified by a battery of centrifugation and filtration steps. The USCs-EVs were then characterized by transmission electron microscopy, western blot and tunable resistive pulse sensing techniques. After intramuscularly transplanting USCs-EVs into an ischemic mouse hind-limb, we observed the therapeutic effects of USCs-EVs on perfusion by laser doppler perfusion imaging, angiogenesis and muscle regeneration by histology and immunohistochemistry techniques over 21 days. We subsequently tested whether USCs-EVs can induce the proliferation of a human microvascular endothelial cell line HMEC-1 and a mouse myoblast cell line C2C12 by cell counting kit 8 assay in vitro. Meanwhile, the potential growth factors in the USCs-EVs and supernatants of the USCs cultures were detected by enzyme-linked immunosorbent assay. Results The USCs-EVs were spherical vesicles with a diameter of 30–150 nm and expressed exosomal markers, such as CD9, CD63 and Tsg101. Ischemic limb perfusion and function were markedly increased in the hind-limb ischemia (HLI) model after USCs-EVs administration. Moreover, angiogenesis and muscle regeneration levels were significantly higher in the USCs-EVs treatment group than in the PBS group. The in vitro experiments showed that USCs-EVs facilitated HMEC-1 and C2C12 cell proliferation in a dose-dependent manner. Conclusions These results revealed for the first time that USCs-EVs efficiently attenuate severe hind-limb ischemic injury and represent a novel therapy for HLI.
机译:背景/目的我们以前的研究表明,人尿来源的干细胞(USC)作为细胞疗法和组织工程的细胞来源具有巨大潜力,并且USC(USCs-EV)分泌的细胞外囊泡(EV)可以预防糖尿病引起的动物模型中的肾脏损伤。本研究旨在评估USCs-EV对缺血修复的影响。方法通过一系列离心和过滤步骤分离和纯化USCs-EV。然后通过透射电子显微镜,蛋白质印迹和可调电阻脉冲传感技术对USCs-EV进行表征。在将USCs-EV肌肉内移植到缺血的小鼠后肢中后,我们通过激光多普勒灌注成像,组织学和免疫组化技术观察了USCs-EV在21天内对灌注的治疗效果。我们随后通过细胞计数试剂盒8体外试验,测试了USCs-EVs是否可以诱导人微血管内皮细胞系HMEC-1和小鼠成肌细胞C2C12的增殖。同时,通过酶联免疫吸附法检测USCs-EVs和USCs培养上清液中的潜在生长因子。结果USCs-EVs是直径为30-150 nm的球形囊泡,并表达外泌体标记,例如CD9,CD63和Tsg101。使用USCs-EVs后肢缺血(HLI)模型中,缺血肢体的灌注和功能显着增加。此外,USCs-EVs治疗组的血管生成和肌肉再生水平明显高于PBS组。体外实验表明,USCs-EVs以剂量依赖性方式促进HMEC-1和C2C12细胞增殖。结论这些结果首次揭示了USCs-EV可有效减轻严重的后肢缺血性损伤,并代表了一种针对HLI的新疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号